Sarepta’s ELEVIDYS Shows Functional Benefits in Older Duchenne Patients

  • Sarepta presented new data at the 2026 World Muscle Society Congress showing ELEVIDYS provides clinically meaningful functional benefits in older ambulatory Duchenne patients (ages 8-12).
  • Treatment demonstrated durable benefits across multiple measures over two years compared to external controls.
  • Additional analysis showed robust micro-dystrophin expression in younger patients (ages 2-3) 12 weeks post-infusion.
  • Safety profile remained consistent with previous findings, with manageable adverse events.

Sarepta’s latest data reinforces the potential of ELEVIDYS to address a critical phase of Duchenne progression, expanding its clinical utility beyond younger patients. The findings come as gene therapies for rare diseases gain traction, with regulators increasingly focused on demonstrating long-term functional benefits. The results could bolster Sarepta’s leadership in Duchenne treatments, though sustained efficacy and regulatory approvals for broader age groups remain key hurdles.

Long-term Efficacy
Whether the observed functional benefits in older patients will be sustained over longer follow-up periods.
Regulatory Expansion
The pace at which Sarepta can secure approval for ELEVIDYS use in younger patients (under 4 years old).
Competitive Positioning
How these data will position ELEVIDYS against emerging gene therapies for Duchenne muscular dystrophy.